EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

EASL Congress 2025

 

7-10 May Amsterdam
Close
N. Poster
Poster title
Applicant name
Status
  TOP-001 Community-based screening of viral hepatitis infections among high risk migrant and refugee populations in Greece, Italy and Spain: 2-year results of the VH-COMSAVAC project Camila A Picchio Received Received
  TOP-002 Disparities in hepatocellular carcinoma screening and in its detection rates in individuals with hepatitis B or C and cirrhosis in Canada Jean Damascene Makuza Received Received
  THU-3 One-stop shop: a bespoke single-point-of-referral clinic enhances linkage to care for ultrasound surveillance of hepatoma in patients diagnosed with advanced fibrosis and cirrhosis via targeted community screening Basil Ahmad Received Received
  WED-008 Micro-elimination of hepatitis C utilizing hepatitis C virus self-testing in a district prison of northern India: a demonstration project AJEET SINGH BHADORIA Received Received
  WED-019 Direct measurement of incidence and prevalence of Hepatitis C infection using the gold-standard of prospective HCV re-testing of people at risk. A national needs assessment of people who inject drugs and of all people who use addiction services in England Beatrice Emmanouil Received Received
  THU-023 Health behaviors significantly modify the sex-specific alcohol-attributable liver-related mortality in the United States. A population-based study Eduardo Vilar Gomez Received Received
  THU-025 Prevalence of and outcomes related to metabolic dysfunction-associated steatotic liver disease (MASLD) in a nationwide cohort: insights from over 23 million individuals in Taiwans national health insurance research database Huei-Tyng Huang Received Received
  THU-027 Vibration-controlled transient elastography dynamics in the general population: longitudinal results from the LiverScreen consortium Jesse Pustjens Received Received
  WED-027 Changes in hepatitis C virus screening and treatment rates in pregnant individuals before and after implementation of universal screening guidelines compared to hepatitis B virus screening during the same time frame Chandler Shapiro Received Received
  THU-031 MASLD impacts general health, quality of life and work productivity Leen Heyens Received Received
  THU-036 Integrating spatial lipidomics with imaging mass cytometry: a novel approach for metabolic profiling of liver fibrosis Aleksandra Gruevska Received Received
  FRI-045 Hepatic stellate cells orchestrate the retention and functional impairment of tissue-resident CD8 T-cells in the fibrotic human liver George Finney Received Received
  TOP-052 Baseline oral microbiome composition in liver transplant recipients can help predict graft dysfunction Rosmy Babu Received Received
  FRI-057 Mucosal-associated invariant T (MAIT) cells possess direct cytotoxic potential against HCC, but are rendered dysfunctional within the tumour microenvironment Junika Pohl-Topcu Received Received
  SAT-061 Impact of NEDDylation on aging and liver senescence: key insights Leidy Estefanía Zapata-Pavas Received Received
  FRI-065 Non-neuronal role of immune cells in liver regeneration Nastaran Fazel Modares Received Received
  TOP-072 Human cirrhotic ascites contains myeloid reprogrammed T-cells capable of enhancing peritoneal immune surveillance Erich Freyer Received Received
  TOP-074 The reelin signaling pathway in lymphatic endothelial cells is a key driver of ductular reaction during liver injury Aarti Sharma Received Received
  FRI-075 Differential granzyme-mediated immune responses in CXCR6PD-1 CD8 T cells in acute versus chronic ALT flares Roni Souleiman Received Received
  THU-076 RIPK3 is a metabolic regulator impacting mitochondrial dysfunction, endoplasmic reticulum stress and tumour development during murine chemical-induced hepatocarcinogenesis André F. L. Cardador Received Received
  THU-077 E7386 enhances lenvatinibs antitumor efficacy and upregulates ATF4 signalling in preclinical models and human hepatocellular carcinoma Agavni Mesropian Received Received
  WED-079 Quantification of genes encoding bacterial sialidases and enzymes of the nan cluster in combination with cutaneous T cell-attracting chemokine (CTACK) in bile for the early detection of cholangiocellular carcinoma in patients with primary sclerosing cholangitis Antonia Triefenbach Received Received
  WED-081 Role of alcohol-associated gut microbiota in driving liver fibrosis via tgfbr1 kinase alterations in alcohol associated liver disease MANISHA YADAV Received Received
  FRI-083 Histologic predictors of response to atezolizumab and bevacizumab in hepatocellular carcinoma biopsies Alexandre Sayadi Received Received
  FRI-086 Long-term survival outcomes in patients receiving atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma: an update of the AB-real study Bernardo Stefanini Received Received
  SAT-089 mRNA-based vaccination for tumor neoantigens to induce a therapeutic T cell response in HCC Paul Schneider Received Received
  WED-090 The mind and monitoring: The psychological impact of hepatocellular carcinoma surveillance Azzra Maricar Received Received
  SAT-091 Using patient-led genetics to identify new therapeutic targets in metastatic cholangiocarcinoma Paula Olaizola Received Received
  TOP-094 Breaking barriers: intensive care admission in patients with advanced HCC on immunotherapy Marta Fortuny Received Received
  THU-103 Impact of PNPLA3 and TM6SF2 single nucleotide polymorphisms in metabolic dysfunction-associated steatohepatitis-linked hepatocellular carcinoma development in 3D extracellular matrix models Giulia Lupo Received Received
  TOP-108 Prevalence and impact of clinically significant portal hypertension (CSPH) in patients with hepatocellular carcinoma (HCC): a multicenter cohort study on the ITA.LI.CA database Rusi Chen Received Received
  SAT-112 Role of hypoxia on the progression and survival of hepatocellular carcinoma in hypoxia-inducible factor 1 alpha knockout bi- and tri-dimensional in vitro models Tania Payo-Serafín Received Received
  FRI-114 Liver resection versus trans-arterial chemoembolization for huge hepatocellular carcinoma (10cm): a nationwide propensity score adjusted analysis Jai Young Cho Received Received
  THU-115 Targeting UBE2I-mediated protein hyper-SUMOylation halts cholangiocarcinoma progression and rewires the tumor-stroma crosstalk Irene Olaizola Received Received
  WED-115 Differential gene expression in hepatocellular carcinoma: a bioinformatic approach to correlate with HIF1A Jennifer Martínez-Geijo Received Received
  WED-118 Shifting etiologies and emerging metabolic factors of hepatocellular carcinoma from 2005 to 2020: a german nationwide population-based study Josune Cabello Calleja Received Received
  SAT-119 Detection of Candida species via shotgun sequencing in patients with decompensated cirrhosis is associated with impaired survival and higher risk of acute-on-chronic liver failure Sarah Lisa Schütte Received Received
  THU-123 YAP activity in cancer-associated fibroblasts is relevant for immune escape in cholangiocarcinoma Kieu Trinh Dinh Received Received
  WED-123 Prognostic significance of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in hepatocellular carcinoma: a retrospective multicentre study on overall survival following hepatectomy or orthotopic liver transplantation Konstantinos Arvanitakis Received Received
  WED-124 National burden of MASH-related liver cancer in the United States 1990 2021: a systematic analysis for trends and patterns of geographic variations of the global burden of disease study Seung Up Kim Received Received
  TOP-128 Efficacy of WNTinib, a novel ive therapeutic for CTNNB1-mutant tumors, in preclinical models of hepatoblastoma Ugne Balaseviciute Received Received
  TOP-129 Perineural invasion drives hilar cholangiocarcinoma progression via epithelial-mesenchymal transition augmented by cancer-associated Schwann cell-derived VGF Honghua Zhang Received Received
  TOP-130 Deep learning derived radiomics with advanced machine learning outperforms clinical biomarkers in predicting outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma Mathew Vithayathil Received Received
  THU-133 Hypoglycemia in People with Cirrhosis without Diabetes Alan Hutchison Received Received
  THU-134 Bone morphogenic protein 9 (BMP9): a novel therapeutic agent for the prevention of circulatory and renal failure in animal models of acute-on-chronic liver failure (ACLF) Alexandra Phillips Received Received
  THU-137 The metabolome of patients with cirrhosis hospitalized with overt hepatic encephalopathy and association with clinical course Anindro Bhattacharya Received Received
  WED-137 Hepatocellular carcinoma after liver transplantation: development of a machine learning-based risk score for safely ruling out recurrence Pedro Passos Received Received
  THU-142 Early detection of hepatic encephalopathy using wearable sensors: preliminary data Clelia Asero Received Received
  WED-155 Validation of hepatocellular carcinoma risk scoring tools in patients with chronic hepatitis B virus and hepatitis C virus infection results from a large multicentre cohort study Yun Jung Kim Received Received
  THU-156 An antimicrobial peptide, melittin attenuates gut urease activity and ammonia production in experimental model of cirrhosis DEEPIKA JAKHAR Received Received
  THU-159 Development and validation of dimethylarginines (DAS) as a novel biomarker to identify pre-ACLF and predict outcomes following acute decompensation of cirrhosis in two prospective multicentre european cohorts Kohilan Gananandan Received Received
  SAT-161 Prevalence and prognosis of cirrhotic cardiomyopathy in hospitalized patients with decompensated cirrhosis cristina Solé Received Received
  THU-162 Profiling of intestinal blood vessel-associated macrophages in cirrhosis Lena Smets Received Received
  SAT-173 History of overt hepatic encephalopathy is associated with worsen cognitive tests and cerebral atrophy in a prospective cohort of outpatients with cirrhosis with multimodal evaluation and brain magnetic resonance imaging with diffusion tensor imaging Lyès Kheloufi Received Received
  SAT-175 Natural history of overt hepatic encephalopathy defining factors associated with progression, resolution and mortality Maria Pilar Ballester Received Received
  SAT-176 Minimal serum creatinine fluctuations impact on prognosis in acutely decompensated cirrhosis Marco Tizzani Received Received
  THU-180 Toll-like receptor 4 inhibition restores cytochrome C oxidase mitigating hyperammonemia-induced hepatocyte mitochondrial dysfunction Supachaya Sriphoosanaphan Received Received
  THU-181 Plasma-induced neutrophil dysfunction is a novel approach to identification of acutely decompensated cirrhosis patients at risk of infection Supachaya Sriphoosanaphan Received Received
  THU-182 Transcriptomic and metabolic insights into hyperammonemia: the complementary therapeutic roles of toll-like receptor 4 inhibitor and ornithine phenylacetate Supachaya Sriphoosanaphan Received Received
  SAT-187 Rehabilitation classes for sarcopenic cirrhotics, a proof of concept Mariana Verdelho Machado Received Received
  TOP-189 Vibration-controlled transient elastography of the liver and the spleen for hepatic decompensation risk stratification in a european multicentre study of contemporary cACLD patients Mathias Jachs Received Received
  TOP-190 Biomarkers of pathophysiological mechanisms identify stage-specific divers of disease progression in ACLD Georg Semmler Received Received
  WED-198 Incidence and clinical significance of recompensation after HCV-cure Georg Semmler Received Received
  WED-199 Advanced chronic liver disease in the context of further decompensation & recompensation a multistate analysis of a contemporary prospective study Georg Semmler Received Received
  TOP-202 Matrix remodeling and versican upregulation in mesenteric lymph nodes modulate bacterial phagocytosis and migration of activated CD4 T cells, fueling systemic bacterial infections in cirrhosis Pinky Juneja Received Received
  FRI-213 The presence of chronic kidney disease does not worsen 28- or 90-day survival in cirrhotic patients with acute on chronic liver failure Sakktivel Elangovan Received Received
  TOP-217 Pathophysiological basis of acute on chronic liver failure (ACLF) triggered by alcohol-related hepatitis or infection using circulating biomarkers of inflammation, circulatory dysfunction and albumin modifications Julian Pohl Received Received
  TOP-233 Sustained improvement in minimal hepatic encephalopathy and quality of life in patients with cirrhosis through two-session fresh fecal microbiota transplantation: An open-label pilot randomized controlled trial (FLAME trial) Ankit Agarwal Received Received
  TOP-235 Impact of growth hormone therapy on complications, disease severity, and frailty in decompensated cirrhosis: a randomized controlled trial Parminder Kaur Received Received
  TOP-236 Neurofilament light chains and glial fibrillary acidic protein for predicting post-TIPS hepatic encephalopathy Simon Johannes Gairing Received Received
  THU-237 Effectiveness and outcomes of routine opt-out screening for hepatitis C in a UK emergency department Samuel Hey Received Received
  SAT-238 To construct a prediction model of recompensation in HBV-related decompensated cirrhosis patients combined with the inflammation index MLR Tang shanhong Received Received
  SAT-241 Over the years, diagnostic problems in cirrhosis continue, but its etiology changes: chronic viral hepatitis is decreasing, steatotic liver disease is increasing Zülal &304;stemihan Received Received
  FRI-243 VDAC1-mediated lipid droplet-mitochondria tethering promotes tumorigenesis and inhibits HBV replication in CHB patients concurrent with MASLD Zhe Dai Received Received
  FRI-245 Hepatitis E virus entry requires the cholesterol transporter NiemannPick C1 Emely Richter Received Received
  SAT-248 End of treatment anti-HBc IgG and HBcrAg levels predict severe flares after NUC cessation Arno Furquim dAlmeida Received Received
  TOP-252 HBsAg decline and clearance with peg-IFN add-on therapy an individual participant data meta-analysis of prospective trials (PROSPER) Edo J. Dongelmans Received Received
  FRI-254 Early immune responses define Peg-IFNa-mediated treatment outcome in chronic hepatitis D virus infection Manfred Anim Received Received
  FRI-262 Isogenic studies of basal-core promoter and precore mutations in hepatitis B genotype c Leon Louis Seifert Received Received
  FRI-263 Viral N6-methyladenosine modifications regulate hepatitis E virus infections Mara Klöhn Received Received
  TOP-266 Association between sustained virological response and adverse liver-related outcomes in patients with decompensated HCV cirrhosis Lisa M. van Velsen Received Received
  FRI-276 Early kinetics of HBV and HDV serum and intrahepatic markers during and after liver transplantation: impact of HBIG and baseline HBsAg levels Sara Battistella Received Received
  TOP-283 Transition of immune tolerant to immune active chronic hepatitis B and potential implications for monitoring and treatment Lisa M. van Velsen Received Received
  WED-285 Real-world evidence shows comparable Bulevirtide effectiveness in hepatitis D patients with and without cirrhosis: results from the prospective nationwide D-Shield multicenter study Maria Paola Anolli Received Received
  SAT-285 Performance of the PAGE-B score for the prediction of hepatocellular carcinoma in chronic hepatitis B patients with metabolic dysfunction Lesley Patmore Received Received
  SAT-286 Risk of hepatocellular carcinoma and other liver-related events in chronic hepatitis B patients with or without hepatitis D virus co-infection Lesley Patmore Received Received
  SAT-287 Metabolic comorbidities are risk factors for adverse liver-related events in individuals with HIV-HBV on tenofovir-based antiretroviral therapy Lesley Patmore Received Received
  SAT-290 Staging liver fibrosis using non-invasive tests in people with chronic hepatitis B (CHB) to inform WHO 2024 guidelines: a systematic review and meta-analysis Antonio Liguori Received Received
  WED-290 Effectiveness and renal safety following switching to tenofovir alafenamide in patients with chronic hepatitis B: Results from a five-year, multicenter cohort study Eiichi Ogawa Received Received
  FRI-291 Targeting hepatitis E virus with an innovative CRISPR-Cas13-based therapeutic approach Yannick Brüggemann Received Received
  WED-292 A cross-sectional, intrahepatic analysis of HBV and HDV markers in liver trasplants of untreated and Bulevirtide-treated patients with chronic hepatitis Delta Elisabetta Degasperi Received Received
  FRI-296 Bile and plasma metabolome reveals association of TMA-TMAO pathway metabolites with gallstone disease progression Vipin Yadav Received Received
  THU-296 Evaluation of response to Ursodeoxycholic acid (UDCA) in a nationwide population with primary biliary cholangitis Ellen Werner Received Received
  TOP-298 Long non-coding RNA SNHG4 is regulated by hepatitis B virus and promotes hepatocarcinogenesis Belal Ahmad Received Received
  FRI-307 IL-27 drives activation of tissue-destructive CD8 T cells and is functionally indispensable in immune checkpoint inhibitor-induced hepatitis Cathrin Gudd Received Received
  WED-309 Response-guided interferon add-on to bulevirtide treatment: updated real-world insights from the austrian hepatitis D cohort study Michael Schwarz Received Received
  FRI-314 Mitochondrial dynamics and auto(mito)phagy are altered in experimental models of primary biliary cholangitis, contributing to disease pathogenesis Irune Lasa-Elosegi Received Received
  THU-320 Diagnostic distribution of patients positive for anti-mitochondrial antibodies (subtype), anti-sp100, and anti-gp210: pathological examination is necessary of PBC diagnosis: a retrospective study based on liver biopsy Hongli Liu Received Received
  THU-322 The risk of psychiatric disorders in patients with autoimmune hepatitis: a nationwide registry-based follow-up study Lisbet Groenbaek Received Received
  TOP-331 Standalone medical therapy versus early endovascular intervention as the first step in the management of patients with primary Budd-Chiari syndrome: a randomized controlled trial Sagnik Biswas Received Received
  WED-333 Recreating Wolman disease in human liver organoids: a new model for pathophisiology and therapeutic exploration Davide Selvestrel Received Received
  SAT-338 The role of metabolic factors in alpha-1 antitrypsin deficiency Christina Schrader Received Received
  WED-338 A promising new treatment for Wilson disease: 64Cu-Methanobactin (ARBM-101) pharmacokinetics examined in animal models by whole-body PET Julie Loft Nagel Received Received
  WED-340 10 year short-term outcomes of a therapeutic stepwise approach involving low-dose systemic thrombolysis for managing acute portomesenteric thrombosis Kohilan Gananandan Received Received
  TOP-345 A 10-year review of obstetric admissions to a quaternary liver intensive care unit: learning from morbidity and mortality Charlotte Sewell Received Received
  TOP-347 Low vitamin B6 status associates with cholangiocarcinoma in primary sclerosing cholangitis Isma Sohail Received Received
  FRI-352 Spatial multiplex analysis reveals distinct senescence patterns and cellular interactions in mouse models of MASLD and MetALD Charalampos Pavlidis Received Received
  FRI-353 Tirzepatide reduces diet-induced senescence and NETosis-mediated liver fibrosis in mice Feng Chen Received Received
  FRI-356 Metabolic dysfunction-associated steatohepatitis (MASH) plays central role in western diet-induced cardiac dysfunction Sandireddy Reddemma Received Received
  SAT-360 Screening, high risk symptomatology and outcomes of Wilsons disease in 56,606 new referrals in a large tertiary psychiatric population James Liu Yin Received Received
  TOP-362 Safety and efficacy of Upadacitinib in patients with primary sclerosing cholangitis and associated colitis Ida Schregel Received Received
  WED-367 Evaluating the influence of obesity and diabetes on fibrosis staging discrepancies in patients with metabolic-associated steatotic liver disease: Comparing liver biopsy and transient elastography Alba Jiménez - Masip Received Received
  SAT-371 Prognostic role of endoscopic ultrasound guided direct portal pressure gradient measurement in porto-sinusoidal vascular disorder Lucia Giuli Received Received
  SAT-374 Health related quality of life in patients with porto-sinusoidal vascular disorder Marina TORRAO GOMES Received Received
  TOP-380 Baseline liver elastography and its longitudinal changes predict liver-related outcomes in patients with metabolic dysfunction associated steatotic liver disease (MASLD) Antonio Liguori Received Received
  WED-389 Cost-effectiveness of hepatic fibrosis screening in suspected MASLD cases in primary care settings DAE WON JUN Received Received
  TOP-393 Liver stiffness as a predictor of major adverse cardiac events in metabolic dysfunction-associated steatotic liver disease Nirbaanjot Walia Received Received
  TOP-396 Extrahepatic multimorbidity, disease clusters and mortality in people with steatotic liver disease in UK Biobank Qi Feng Received Received
  FRI-397 NMR-based metabolic signature reveals the vicious circle between fasting and feeding in homozygous carriers of the PNPLA3 I148M variant in MASLD Lina Jegodzinski Received Received
  SAT-397 Long-term clinical outcomes, efficacy, and safety of transjugular intrahepatic portosystemic shunt in Budd Chiari syndrome Shekhar Swaroop Received Received
  THU-398 Endothelial dysfunction and metabolic dysfunction-associated steatotic liver disease: is there a relationship? Kateryna Pivtorak Received Received
  THU-399 The relationship between insulin resistance, thyroid gland dysfunction and bacterial overgrowth syndrome in the development of vascular complications in patients with metabolic dysfunction-associated steatotic liver disease Kateryna Pivtorak Received Received
  FRI-400 Impact of ageing on metabolic dysfunction-associated steatotic liver disease in a murine model: insights into progression, biomarkers, and therapeutic stratification Lucia Lameroli Mauriz Received Received
  TOP-411 Disease state transitions across the spectrum of steatotic liver disease significantly affect long-term incidence of cirrhosis among a national cohort of veterans in the United States Mai Sedki Received Received
  FRI-419 Therapeutic potential of targeting processing-bodies in metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma Noémie Gellée Received Received
  TOP-426 Lipidomics crosstalk with hepatic stellate cells and macrophages in people with metabolic dysfunction-associated steatotic liver disease Dan Wang Received Received
  THU-429 Volatile organic compound metabolites in urine are associated with MASLD and fibrosis: an environmental health study Laurens A. van Kleef Received Received
  THU-430 Weight loss was associated with risk reduction of MASLD, at-risk MASH and fibrosis with ongoing effects beyond the current recommendations Laurens A. van Kleef Received Received
  TOP-442 Somatic mutation in early stage metabolic-dysfunction associated steatotic liver disease (MASLD) Georgeina L Jarman Received Received
  WED-445 A comparison of the prognostic value of 12 body composition markers for MASLD, at-risk MASH and Increased liver stiffness in a general population setting Laurens A. van Kleef Received Received
  FRI-446 Metabolomic profiling reveals early biomarkers of gestational diabetes mellitus with MASLD as a mediator Won Kim Received Received
  FRI-455 The impact of donor and recipient HSD17B13, PNPLA3 and TM6SF2 genotype on post-transplant fibrosis, steatosis and survival in liver transplant recipients Maria Rosina Troppmair Received Received
  TOP-457 Statin, but not aspirin use, is inversely associated with steatotic liver disease and liver fibrosis: results from two large population based studies Jesse Pustjens Received Received
  TOP-459 MetALD has a higher rate of extrahepatic cancer and cardiovascular events compared to other subtypes of steatotic liver disease Katrina Pekarska Received Received
  SAT-472 Misclassification of alcohol use disorder in MASLD and MetALD: prevalence, clinical characteristics, and outcomes DAE WON JUN Received Received
  TOP-474 Bio-molecular characterization of albumin identifies predictors of disease severity and early mortality in severe alcohol associated hepatitis SUSHMITA PANDEY Received Received
  FRI-489 Coronary angiography in the preoperative work-up for liver transplantation (LT): a multicenter italian cohort study Margherita Saracco Received Received
  FRI-492 Torque Teno virus as a biomarker of immune status and attenuated immune response to vaccination in liver transplant recipients Ezequiel Mauro Received Received
  THU-496 Allied health professionals are essential for facilitating initial evaluation and optimisation of patients for liver transplantation Abigail Greenwell Received Received
  THU-500 Community liver health checks are a valuable tool to support early diagnosis of liver disease Bethia Featherstone Received Received
  SAT-502 Prevalence and predictors of early re-hospitalization or death among a national cohort of veterans hospitalized for alcohol-associated hepatitis in the United States Robert Wong Received Received
  SAT-509 Affinity-tuning chimeric antigen receptors could improve the therapeutic efficacy of regulatory t cells in liver transplantation Ada Kurt Received Received
  THU-513 Should all patients referred for liver transplantation undergo a review in a dedicated multidisciplinary assessment clinic prior to formal liver transplant work up? Katie McCollum Received Received
  THU-514 Patient-perceived quality of care effectiveness of the quality liver nursing care model Maria Hjorth Received Received
  THU-516 Nurse-led clinic for patients with decompensated liver cirrhosis Palle Bager Received Received
  THU-519 Prescribing for pain and symptom management in hospital patients with advanced liver disease: a single centre, retrospective clinical audit Sarah Phillips Received Received
  TOP-522 Health-related quality of life, events of decompensation and mortality effectiveness of the quality liver nursing care model Maria Hjorth Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
10:52
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

EASL Congress 2025

 

7-10 May Amsterdam
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 07/05/2025 TO 10/05/2025
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                   DOI: 10.3252/pso.eu.EASL2025.2025 




PosterSessionOnline
Logo Draft
 
Logo Cert